近日,中国生物制药发布LM-299对外授权合作顺利,3亿美元里程碑将于近期收款的自愿公告。披露礼新医药与默沙东就LM-299/MK-2010 “PD-1/VEGF双抗”的对外授权合作进展顺利,本集团将于近期收到3亿美元的技术转移里程碑付款。2025年7月29日,默沙东在二季度业绩会上披露,LM-299的技术转移已于7月完成,预计将于第三季度确认3亿美元的技术转移里程碑款项。此外,在电话会问答环节,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.